Publicaciones en colaboración con investigadores/as de University of Texas MD Anderson Cancer Center (24)

2024

  1. Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial

    Journal of Clinical Oncology, Vol. 42, Núm. 1, pp. 47-58

  2. Efficacy of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors by Enrollment HER2 IHC Status: Post Hoc Analysis of DESTINY-PanTumor02

    Advances in Therapy

2023

  1. Outcomes and endpoints of relevance in gynecologic cancer clinical trials

    International Journal of Gynecological Cancer, Vol. 33, Núm. 3, pp. 323-332

2022

  1. Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup

    The Lancet Oncology, Vol. 23, Núm. 8, pp. e374-e384

2021

  1. Corrigendum to ‘The forefront of ovarian cancer therapy: update on PARP inhibitors': [Annals of Oncology 31 (2020) 1148–1159] (Annals of Oncology (2020) 31(9) (1148–1159), (S0923753420398914), (10.1016/j.annonc.2020.06.004))

    Annals of Oncology

2020

  1. COVID-19 Global Pandemic: Options for Management of Gynecologic Cancers

    Obstetrical and Gynecological Survey

  2. COVID-19 Global Pandemic: Options for Management of Gynecologic Cancers

    International Journal of Gynecological Cancer

  3. PD-1 blockade in recurrent or metastatic cervical cancer: Data from cemiplimab phase I expansion cohorts and characterization of PD-L1 expression in cervical cancer

    Gynecologic Oncology, Vol. 159, Núm. 2, pp. 322-328

  4. The forefront of ovarian cancer therapy: update on PARP inhibitors

    Annals of Oncology, Vol. 31, Núm. 9, pp. 1148-1159

2019

  1. Updates and management algorithm for neuroendocrine tumors of the uterine cervix

    International Journal of Gynecological Cancer, Vol. 29, Núm. 6, pp. 986-995

2018

  1. OV21/PETROC: A randomized Gynecologic Cancer Intergroup phase II study of intraperitoneal versus intravenous chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer

    Annals of Oncology, Vol. 29, Núm. 2, pp. 431-438

  2. Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer

    Gynecologic Oncology, Vol. 151, Núm. 1, pp. 46-52

2017

  1. Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial

    The Lancet Oncology, Vol. 18, Núm. 6, pp. 743-754

2016

  1. ESMO-ESGO-ESTRO consensus conference on endometrial cancer: Diagnosis, treatment and follow-up

    Annals of Oncology, Vol. 27, Núm. 1, pp. 16-41

  2. Routine Clinical Practice for Patients with Recurrent Ovarian Carcinoma: Results from the TROCADERO Study

    International Journal of Gynecological Cancer, Vol. 26, Núm. 2, pp. 240-247

2015

  1. A critical appraisal of hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of advanced and recurrent ovarian cancer

    Gynecologic Oncology, Vol. 136, Núm. 1, pp. 130-135

  2. Prospective study of the impact of the Prosigna assay on adjuvant clinical decision-making in unselected patients with estrogen receptor positive, human epidermal growth factor receptor negative, node negative early-stage breast cancer

    Current Medical Research and Opinion, Vol. 31, Núm. 6, pp. 1129-1137

  3. SEOM guidelines for cervical cancer

    Clinical and Translational Oncology, Vol. 17, Núm. 12, pp. 1036-1042

2014

  1. SEOM guideline in ovarian cancer 2014

    Clinical and Translational Oncology, Vol. 16, Núm. 12, pp. 1067-1071

  2. Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): A randomised, open-label, phase 3 trial

    The Lancet Oncology, Vol. 15, Núm. 7, pp. 689-699